Cardiovascular Revascularization Medicine Volume 34 to 45

Cardiovascular Revascularization Medicine (CRM) stands as an influential international journal, presenting original laboratory and clinical investigations focused on revascularization therapies in cardiovascular medicine. With a commitment to multidisciplinary perspectives, CRM publishes 12 regular print issues annually, supplemented by an additional special issue. Indexed on Index Medicus and MEDLINE®/PubMed®, the journal plays a pivotal role in disseminating cutting-edge research and insights to a global audience.

Key features and characteristics of CRM include:

1. Scope and Focus: CRM encompasses a broad spectrum of topics within cardiovascular medicine, addressing preclinical and clinical work. This includes pharmacological interventions, restenosis management, percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, congenital heart disease, coronary heart disease, genetics and translational science, health services and outcomes research, invasive imaging, regulatory and health policy, technology and innovation, and vascular medicine.
2. Global Influence: The journal, positioned in Washington, DC, provides a unique advantage in reporting on regulatory issues relevant to interventional cardiology and structural heart disease. Its readership spans cardiologists, interventional cardiologists, structural heart interventionalists, vascular physicians, healthcare regulators, industry professionals, fellows in training, and innovators worldwide.
3. Official Journal of CRT Meeting: As the official journal of the Cardiovascular Research Technologies (CRT) meeting, CRM plays a pivotal role in reflecting the latest research and innovations discussed at this premier event. The journal aligns its content with the tracks of the CRT meeting, covering Complex Coronary, Valve and Structural, Endovascular, Imaging and Physiology, Atherosclerosis, Cardiogenic Shock, Technology and Innovation, Regulatory and Healthcare Policy, and Innovations.
4. Competition and Distinctiveness: CRM’s nearest competitors include JACC: Cardiovascular Interventions, Circulation: Cardiovascular Interventions, and EuroIntervention. The journal distinguishes itself through its singular focus on cardiovascular revascularization and structural intervention, offering a unique platform for clinicians and researchers in the field.
5. Article Types and Peer Review: CRM welcomes a variety of article types, including original articles, research letters, reviews, editorials, and special features. The single-blind peer-review process ensures the rigor and quality of published content.

In summary, Cardiovascular Revascularization Medicine emerges as a leading journal at the intersection of laboratory and clinical research, contributing significantly to the advancement of cardiovascular revascularization therapies and structural interventions. Its global reach, association with the CRT meeting, and commitment to diverse aspects of cardiovascular medicine position CRM as a vital resource for professionals in the field.

Volume 34: Pages 1-156 (January 2022)

Volume 35: Pages 1-196 (February 2022)

Volume 36: Pages 1-170 (March 2022)

Volume 37: Pages 1-158 (April 2022)

Volume 38: Pages 1-132 (May 2022)

Volume 39: Pages 1-128 (June 2022)

Volume 40: Pages 1-212 (July 2022)

Volume 41: Pages 1-182 (August 2022)

Volume 42: Pages 1-188 (September 2022)

Volume 43: Pages 1-162 (October 2022)

Volume 44: Pages 1-108 (November 2022)

Volume 45: Pages 1-88 (December 2022)